Neoadjuvant Anti-PD-1 Alone or in Combination with Anti-TIGIT or an Oncolytic Virus in Resectable Stage IIIB–D Melanoma: A Phase I/II Trial

Investigators reported the primary analysis of safety and antitumor activity in the pembrolizumab plus vibostolimab, pembrolizumab plus gebasaxturev, and pembrolizumab monotherapy treatment arms, including a post hoc biomarker analysis.